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Abstract: Squamous cell carcinoma of the hypopharynx rep-
resents a distinct clinical entity. Most patients present with signiﬁ-
cant comorbidities and advanced-stage disease. The overall
survival is relatively poor because of high rates of regional and dis-
tant metastasis at presentation or early in the course of the disease.
A multidisciplinary approach is crucial in the overall management
of these patients to achieve the best results and maintain or
improve functional results. Traditionally, operable hypopharyngeal
cancer has been treated by total (occasionally partial) laryngec-
tomy and partial or circumferential pharyngectomy, followed by
reconstruction and postoperative radiotherapy in most cases.
Efforts to preserve speech and swallowing function in the
surgical treatment of hypopharyngeal (and laryngeal) cancer
have resulted in a declining use of total laryngopharyngectomy
and improved reconstructive efforts, including microvascular
free tissue transfer. There are many surgical, as well as non-
surgical, options available for organ and function preservation,
which report equally effective tumor control and survival. The
selection of appropriate treatment is of crucial importance in
the achievement of optimal results for these patients. In this ar-
ticle, several aspects of surgical and nonsurgical approaches
in the treatment of hypopharyngeal cancer are discussed.
Future studies must be carefully designed within clearly
deﬁned populations and use uniform terminology and standar-
dized functional assessment and declare appropriate patient
or disease endpoints. These studies should focus on improve-
ment of resultsx, without increasing patient morbidity. In this
respect, technical improvements in radiotherapy such as inten-
sity-modulated radiotherapy, advances in supportive care, and
incorporation of newer systemic agents such as targeted ther-
apy, are relevant developments. VC 2010 Wiley Periodicals, Inc.
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Squamous cell carcinoma of the hypopharynx is less
prevalent than at most other major sites of the head
and neck, such as the oral cavity, larynx and orophar-
ynx, and accounts for approximately 3% to 5% of all
head and neck squamous cell carcinomas (HNSCC).1,2
Tumors arising in the hypopharynx have their own
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speciﬁc and unique characteristics and considerations
regarding treatment. A high proportion of the
patients are heavy drinkers of alcohol and have addi-
tional signiﬁcant comorbidities.1 Most patients when
diagnosed have advanced-stage disease. Approxi-
mately 70% to 85% of the patients reported in large
series have stage III or IV disease at presentation,
and the 5-year overall survival rate is reported to be
around 15% to 45%.1–7 The anatomic proximity of the
larynx, advanced stage of disease at presentation,
and higher rates of regional and distant metastasis
portend a worse prognosis compared with other head
and neck cancer sites and are factors that require
consideration when making treatment decisions.
As reviewed by Gourin and Terris,8 the important
factors in this dismal prognosis in patients who pres-
ent with a hypopharyngeal cancer are the high rates
of regional and distant metastasis. Approximately
60% to 80% of the patients have clinically apparent
tumor involved regional lymph nodes, and contralat-
eral occult nodal metastases are present in nearly
40% of cases.9 The number of patients with develop-
ment of distant metastasis, reported to be between
10% and 30% or even higher, is an even more impor-
tant prognostic factor. Distant metastatic spread has
been reported to occur in up to 60% of hypopharyng-
eal cancer cases,10 either at presentation or during
follow-up, and is more frequent compared with other
HNSCCs. Predominant sites of systemic dissemina-
tion are the lung, mediastinal lymph nodes, liver, and
bone. These patients are usually treated in the con-
text of various study protocols in which median sur-
vival is typically less than a year.
In an epidemiologic study of a series of 595
patients with hypopharyngeal cancer in Ontario, Can-
ada, Hall et al1 reported that almost 50% of the
patients had recurrences, most within 12 months af-
ter completion of treatment. Fifty percent of these
recurrences involved distant metastasis. Multicentric-
ity is also a common pathologic feature of hypophar-
yngeal cancers, as well as considerable submucosal
spread, and, when treated surgically, the margins of
excision frequently demonstrate the presence of tumor.
Airway and nutritional issues are difﬁcult problems in
patients presenting with advanced hypopharyngeal can-
cer. Soft tissue extension of the disease involving the
constrictor musculature, the soft tissues of the neck,
and the parapharyngeal space is quite common.
TREATMENT CHOICES
Traditionally, laryngopharyngectomy with reconstruc-
tion of the pharynx has been the preferred initial
treatment modality for hypopharyngeal cancers. In
an attempt to limit the morbidity of surgical therapy,
nonsurgical treatments have gained popularity. How-
ever, treatment with radiotherapy alone is reported to
have a worse prognosis compared with combined
treatment with surgery and radiotherapy, particularly
in stage IV disease.3,6,11 The addition of chemother-
apy to primary radiotherapy protocols results in out-
comes comparable to surgery and postoperative
radiotherapy, but with the advantage of larynx pres-
ervation in a large number of cases.12 However,
unlike advanced laryngeal cancers, the question of
organ preservation in hypopharyngeal cancer has not
been thoroughly evaluated, precluding ﬁrm conclu-
sions as to which is the optimal treatment.13,14
The terms ‘‘organ preservation’’ and ‘‘larynx pres-
ervation’’ in particular are frequently unclearly
deﬁned or interpreted. In fact, the terms only mean
that the organ has been left anatomically intact and
free from surgical intervention but are not indicative
of function. Therefore, organ preservation should not
be confused with function preservation. With regard
to hypopharyngeal cancer, function includes both
voice and swallowing and, in a broader sense, quality
of life. Function may even be better preserved after
removal of the organ, permitting aspiration free de-
glutition and prosthetic voice than by leaving intact a
functionless larynx. Formal studies on this subject
are lacking, but physicians involved with this prob-
lem are well aware of its existence. In many cases it
may be more important to the patient to preserve or
restore function rather than to simply preserve an
intact but poorly functioning larynx. Stimulated by
past experiences and observations, a multidisciplinary
international group of experts recently evaluated
results from pertinent phase III clinical trials and
meta-analyses with the aim of developing guidelines
for the conduct of contemporary phase III larynx
preservation trials. Emphasis was made in these
guidelines on reﬁning the deﬁnition of a functional
larynx within a context of organ preservation treat-
ment strategies and to determine the best methods
for assessment of function.15
Moreover, larynx preservation as a treatment
strategy, although intended to preserve the organ,
includes the option of surgical salvage in cases of per-
sistent or recurrent disease in an effort to obtain opti-
mal patient survival rates comparable to those of
primary surgery followed by postoperative (chemo)ra-
diotherapy. Thus organ preserving strategies as a concept
for curative treatment are not exclusively nonsurgical.
Neck dissection or irradiation is usually part of the
initial treatment of hypopharyngeal cancer because of
the high rate of clinically apparent, as well as occult,
nodal metastasis. The primary echelon drainage is to
the jugular chain (levels II to IV), but the retropharyng-
eal and level VI nodes are all at risk.16 In elective treat-
ment of occult regional metastasis, the high incidence
of retropharyngeal and paratracheal metastasis,17 as
well as the high rate of contralateral metastasis,9
should be considered. The low incidence or even ab-
sence of nodal metastasis found in sublevel IIB and
level I, in particular, may justify the preservation of
these levels in the elective treatment of the N0 neck in
patients with hypopharyngeal cancer.18–20 The several
treatment options for hypopharyngeal carcinoma will be
discussed.
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PRIMARY SURGERY
For decades, the treatment protocol that afforded the
best oncologic outcomes for hypopharyngeal cancer
consisted of radical surgery and postoperative radio-
therapy. More recently, the role of initial surgery has
been diminished in favor of nonsurgical treatment reg-
imens of radiotherapy combined with platinum-based
chemotherapy. However, in early-stage disease, sur-
gery is still a treatment option. Also, in cases of exten-
sive disease, when most patients will already have
seriously impaired laryngeal and hypopharyngeal
function, surgery with adequate reconstruction, fol-
lowed by radiotherapy, may have both the best func-
tional and oncologic outcomes.
Three surgical options are available for treatment
of hypopharyngeal cancer: ‘‘radical’’ open surgery
[total laryngopharyngectomy (TLP) or total laryngec-
tomy with partial pharyngectomy], partial open sur-
gery (partial laryngectomy with pharyngectomy), and
partial transoral (or minimally invasive) surgery.
Total Laryngopharyngectomy. Traditionally, lesions
that involve more than two thirds of the circumfer-
ence of the hypopharynx have been treated by radical
surgery, consisting of total laryngectomy and circum-
ferential pharyngectomy, including varying amounts
of cervical or even thoracic esophagus, followed by
radiotherapy in most cases. The 5-year disease-spe-
ciﬁc survival rate has been reported to be between
40% and 50%.4,21,22 Postoperative chemoradiotherapy
is reported to further improve tumor control.23
The resulting surgical pharyngoesophageal defects
require reconstruction and institutional preferences
often depend on factors such as the training specialty
of the surgical team and the expertise of the available
team.24 Hypopharyngeal reconstruction has been a
major challenge over the years. The deltopectoral ﬂap
was the only reconstructive approach before the pec-
toralis myocutaneous ﬂap became available in the
1970s. The pectoralis myocutaneous ﬂap is a reliable
reconstructive method for lesions with minimal exten-
sion into the esophagus and has proved useful in
severely depleted or elderly patients.25,26 This ﬂap, or
other myocutaneous ﬂaps are also useful as an onlay
patch pharyngoplasty, when a partial pharyngeal defect
has been created. Gastric ‘‘pull-up’’ or transposition is
generally recommended for tumors that have extended
as far as the middle third of the esophagus or where
the resected lower margin is deeply placed within the
mediastinum, making any safe surgical repair difﬁcult.
However, there is a considerable learning curve in per-
forming gastric transposition, which requires careful
coordination between the head and neck and thoracic
surgeons. More recently the introduction of microvascu-
lar and free ﬂap reconstruction has revolutionized the
surgical approaches and functional results in hypophar-
yngeal cancer, both for ‘‘patch’’ or circumferential recon-
struction. Microvascular ﬂaps commonly used are jejunum,
radial forearm free ﬂap, or anterolateral thigh ﬂap.
Fasciocutaneous free ﬂap, anterolateral thigh ﬂap,
and radial forearm free ﬂap reconstructions are cur-
rently being used more frequently than the intestinal
ﬂaps because of reliability, technical accessibility, and
popularity with surgeons.27 Functional outcomes have
been reported to be better with modern fasciocutane-
ous free ﬂap reconstruction compared with the tradi-
tional jejunal ﬂap, and the donor site morbidity is
reported as minimal.27,28 However, the morbidity after
ﬂap reconstruction is reported to be considerable. In a
large surgical series of 153 patients (involving 85 par-
tial and 68 circumferential pharyngectomies, and
about 50% of patients had surgery after previous
radiotherapy), ﬁstulas and wound complications were
seen in 33% and 25% of cases, respectively. The late
complication and stricture rates were 26% and 15%,
respectively, and 16% of patients required permanent
feeding through a gastrostomy tube. It was also
reported that only 44% of patients had surgical voice
restoration with a tracheoesophageal puncture.29
Partial Surgery. More conservative surgical proce-
dures have been used for the treatment of hypophar-
yngeal cancer. As surgical organ preserving
procedures, endoscopic (laser) microsurgery, endoscopic
robotic surgery, lateral pharyngectomy, and hemilar-
yngopharyngectomy are possible endoscopic and exter-
nal approaches described. However, these procedures
can only be considered in selected cases, usually early
(T-stage) cancer, and the choice of such limited surgical
procedures must recognize that hypopharyngeal cancers
have a high predilection to extensive submucosal tumor
spread.
Open Procedures. For tumors arising in the upper
part of the pyriform sinus or the aryepiglottic fold, a
supraglottic hemilaryngopharyngectomy can be used.
Although the technique had been used for many deca-
des, one of the ﬁrst large series of supraglottic laryn-
gectomy and partial pharyngectomy for cancers of the
pyriform sinus was published in 1980 by Ogura
et al.30 In this series of 175 patients treated for carci-
noma of the pyriform sinus; 85 underwent partial lar-
yngopharyngectomy (PLP); 57, TLP; and 33, palliative
radiation. The actuarial 3-year survival rate was 59%
for the PLP-treated group, 36% for the TLP-treated
group, and 11% for the palliation group. The better
outcome for the PLP-treated group as compared with
the TLP-treated group should be attributed to selec-
tion of lower-staged tumors eligible for this treatment.
In 1993, Laccourreye et al31 reported on a series
of patients treated between 1964 to 1985 with a
supracricoid hemilaryngopharyngectomy (SCHLP)
performed on selected pyriform sinus carcinomas clas-
siﬁed as T2. Tumors with invasion of the apex of the
pyriform sinus, of the postcricoid region, of the
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posterior pharyngeal wall, or with ﬁxation of the true
vocal cord were excluded from this study. This tech-
nique was aimed at preserving physiologic phonation,
respiration, and swallowing while achieving the same
local control rate as a pharyngolaryngectomy. Patients
were followed up for at least 6 years or until death.
Five-year actuarial locoregional control was reported
at 95% with a 5-year disease-speciﬁc survival rate of
56%. The 5-year actuarial local recurrence rate was
3.4%. The author considered the SCHLP technique to
be a safe method of voice preservation in selected cases
of pyriform sinus carcinoma. In 2005, the same group
reported on SCHLP performed on 147 patients over a
19-year period. All patients had previously untreated
invasive squamous cell carcinoma of the pyriform
sinus.32,33 Before surgery, almost all (97%) of the
patients had a cisplatin-based induction chemotherapy
regimen. A complete clinical response and a complete
histopathologic regression were noted in 22% and 17%
of patients, respectively. Postoperative radiotherapy
was given in approximately 50% of patients. The 5-
year actuarial local control estimate was 90%, and the
overall laryngeal preservation rate was 91%. On
regression analysis, positive resection margins and
invasion of the apex of the pyriform sinus were identi-
ﬁed as adverse factors for predicting local recurrence.
In another series of 48 selected cases treated by
the same technique of induction chemotherapy fol-
lowed by surgery, all T1 or T2 and arising at the pyri-
form sinus or aryepiglottic fold, the 5-year survival
rate was 47%.34 All patients achieved deglutition
without aspiration by the end of the ﬁrst postopera-
tive month. All but 5 patients received postoperative
radiotherapy. Postoperative death or prior radiother-
apy was the reason for not undergoing radiotherapy.
All patients had ipsilateral (radical) neck dissection.
Neck recurrence was 15%, and local recurrence was
2%. Other series report similar results with 5-year
overall survival rates around 50%, and disease-spe-
ciﬁc survival rates of 60% to 65% in these selected
cases, mostly treated with postoperative radiotherapy
and a larynx preservation rate in the order of
80%.35,36
Transoral (Minimally Invasive) Procedures. Transo-
ral laser surgery (TOLS) was initially employed for
the resection of laryngeal cancers,37,38 but its use was
later extended to hypopharyngeal cancer.39,40 Zeitels
et al39 was one of the ﬁrst to publish on TOLS for
supraglottic and hypopharyngeal cancer. He reported
on 45 cases, of which 22, mostly classiﬁed T1, had
TOLS only, and 23 with locally more extensive tumors,
but all N0, received additional radiotherapy locally and
to the neck. Seven of the 23 cases had positive margins,
and 5 (26%) of these failed locoregionally.
Steiner et al41 retrospectively reviewed 129 previ-
ously untreated patients with squamous cell carci-
noma of the pyriform sinus treated by TOLS. Of these,
24 tumors were staged as pT1, 74 as pT2, 17 as pT3,
and 14 as pT4. Overall, 68% of these patients had nodal
metastases. Of all cases, treatment consisted of TOLS
and neck dissection surgery alone in 42%, and 58% also
underwent postoperative radiotherapy. The 5-year over-
all survival rate was 71% for patients with stage I and
II disease, and 47% for patients with stage III and IV
disease. The reported 5-year recurrence-free survival
rate for stage I/II and stage III/IV disease was 95% and
69%, respectively.
Rudert and Ho¨ft42 reported a 100% larynx and
pharynx organ preservation rate with a 5-year overall
survival rate of 48% and disease-speciﬁc survival rate
of 58% in a series of 29 predominantly T1 and T2 hypo-
pharyngeal tumors. All but 3 patients underwent post-
operative radiotherapy, and all but 4 underwent neck
dissection. In this selected group, no symptomatic alter-
ation in swallowing was reported, and the technique
was considered suitable for cancers of the posterior
hypopharyngeal wall, in particular.
In a series by Vilaseca et al43 of 28 patients treated
with TOLS, 21% (6 patients) had stage II disease, 29
% (8 patients) stage III, and 50% (14 patients) stage IV.
All patients underwent unilateral or bilateral neck dis-
section. Of these patients, 43% had radiotherapy to the
neck, and 14% had radiotherapy locoregionally. Of the
14 patients alive and without disease in the follow-up
period, 11 (79%) had their larynx functionally pre-
served, but 3 (21%) were gastrostomy dependent.
Kutter et al44 analyzed 55 consecutive patients with
pharyngeal or pharyngolaryngeal squamous cell carci-
noma (24 ¼ T1, 28 ¼ T2, 3 ¼ T3) treated with TOLS.
Neck dissection was performed in 43 patients. In this
group, the 2-year overall survival rate was 78%, and
local control was 90%.
Martin et al45 reported on a larger series of 172
patients with hypopharyngeal cancer treated from
1986 to 2003 with TOLS, of whom 15% had stage I
and II disease and 85% had stage III and IV disease.
Of these tumors, 87% originated in the pyriform sinus.
The 5-year overall survival rate was 68% for stage I
and II, 64% for stage III, and 41% for stage IV. In this
series 52% underwent postoperative chemoradiation,
and 91% underwent unilateral or bilateral neck dissec-
tion. Only 1 patient required laryngectomy for func-
tional reasons, and 6 patients had permanent
gastrostomy tubes.
In summary, the oncologic results of TOLS
appear comparable with open approaches, with a 5-
year overall survival rate of around 50% to 70% in
stage I and II disease and 40% to 50% in stage III
and IV disease. The disease-speciﬁc survival rate
with TOLS is on the order of 60% and is associated
with high rates of larynx preservation in these
selected cases. However, most patients continue to
require postoperative radiotherapy.
Transoral robotic surgery is a minimally invasive
surgical technique with the carbon dioxide laser and
is currently used for treatment in selected cases and
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selected sites of head and neck cancers. However, the
hypopharynx is not optimally accessible for this tech-
nique. Published series contain very small numbers of
hypopharyngeal cancer cases and mention the ary-
epiglottic fold or posterior wall as primary tumor sites
suitable for this approach.46–48
PRIMARY CHEMOTHERAPY OR BIO-RADIOTHERAPY
As mentioned before, the results of primary deﬁnitive
radiotherapy followed by salvage surgery when indi-
cated, compared to initial surgery with postoperative
radiotherapy, are reported to be inferior in terms of
survival, particularly for advanced stage tumors.13,49
However, in early-stage hypopharyngeal cancer simi-
lar results can be obtained with deﬁnitive radiother-
apy regimens50 with overall survival and disease-
speciﬁc survival rates reported to be comparable to
those after total laryngectomy or larynx-conserving
surgery.51–53
In the 1990s, the ﬁrst reports on larynx preserva-
tion strategies became available. In 1994, the initial
report of a phase III study conducted by the Depart-
ment of Veterans Affairs Laryngeal Cancer Study
Group was published.54 Patients with stage III-IV la-
ryngeal cancer were randomly assigned to receive 2
cycles of induction chemotherapy with cisplatin and
5-ﬂuorouracil. Those responding (partial or complete)
received a third cycle, followed by radiotherapy.
Patients not responding clinically to the initial cycles
of chemotherapy were offered a total laryngectomy.
Survival rates at 2 years appeared to be comparable
to surgery followed by radiotherapy (68% for both
treatment groups), and the larynx was preserved in
approximately two thirds of the cases. However, pat-
terns of ﬁrst recurrence differed signiﬁcantly between
the 2 arms, with local recurrences occurring more fre-
quently in the chemotherapy-radiotherapy arm,
whereas distant metastases were more common in
the surgically treated patients. Overall, there were no
signiﬁcant differences in eventual rate of distant me-
tastases or in cause of death. However, none of these
patients were treated for hypopharyngeal cancer.
One of the few randomized phase III trials on
hypopharyngeal cancer speciﬁcally comparing the
results of initial surgical versus nonsurgical treat-
ment was conducted by the European Organization
for Research and Treatment of Cancer (EORTC).12 El-
igible patients with hypopharyngeal or epilaryngeal
cancer were randomized between induction PF fol-
lowed by deﬁnitive radiotherapy versus surgery with
postoperative radiotherapy. No differences were found
in local or regional recurrence and disease-free sur-
vival rates at 5 years. The disease-free survival rate
at 5 years was 25% in the induction chemotherapy
arm and 27% in the immediate surgery arm. In this
study, the survival rate with a functional larynx in
the chemoradiation group after 5 year was 35%,
which is similar to other studies.8 This larynx preser-
vation rate appears to be inferior compared with that
for laryngeal cancer, but it should be emphasized that
the 2 endpoints are difﬁcult to compare. First, in the
Veterans Affairs Laryngeal Cancer Study Group trial,
the larynx preservation rate was reported at 2 years
instead of 5 years as in the EORTC study. Moreover,
in the EORTC study, the endpoint was referred to as
survival with a functional larynx (ie, without local dis-
ease, tracheotomy, feeding tube, or gastrostomy).
Recently, the EORTC reported on their second lar-
ynx preservation study.55 In this study, patients with
resectable carcinoma of the larynx (T3-T4, N0-N2) or
hypopharynx (T2-T4, N0-N2), were randomly
assigned to receive induction chemotherapy followed
by radiotherapy in the responders, as described ear-
lier, or an alternating chemoradiation regimen,
including a total of 4 cycles of PF (in weeks 1, 4, 7,
and 10) alternated with radiotherapy, 20 Gy during
the three 2-week intervals between chemotherapy
cycles (60 Gy total). The number of laryngeal and
hypopharyngeal cancers was well balanced between
the 2 arms. Again, the same primary endpoint was
used: survival with a functional larynx. The 2 arms
showed similar results, as they did with regard to
overall survival, progression-free survival, and acute
and late toxicity. It should be emphasized that in the
alternating chemoradiation arm, the total dose of
radiation was reduced to 60 Gy compared with 70 Gy
in the sequential arm, and that the overall treatment
time of radiation was prolonged as a result of the
alternating schedule from 7 weeks to 8 weeks or
more. Therefore, it cannot be concluded from this
study that sequential chemoradiation provide similar
results to conventional concomitant chemoradiation
with 70 Gy of radiation with standard fractionation and
3 courses of cisplatin 100 mg/m2 in weeks 1, 4, and 7.
In 2003, Forastiere et al56 reported on the results
of the RTOG 91-11, a phase III study in which patients
with glottic and supraglottic tumors (T2–T4) were ran-
domly assigned to receive induction PF followed by
radiotherapy in responders, concomitant cisplatin-
based chemoradiotherapy, or radiotherapy alone.
Although overall survival rates were similar in all 3
treatment arms, the highest rate of larynx preserva-
tion was observed after concomitant chemoradiation
(88% vs 75% in the induction chemotherapy arm vs
70% in the radiotherapy alone arm), which also
resulted in superior locoregional control (78% vs 61%
vs 56%). But again this trial included laryngeal and
not hypopharyngeal cancer. A trial update in 2006
conﬁrmed these results.57 It should be noted that in
the initial report, salvage total laryngectomy after
these organ preservation treatment strategies was
associated with acceptable morbidity rates
and resulted in excellent locoregional control,
although the survival rate at 2 years for patients
requiring salvage total laryngectomy was lower than
for patients remaining disease-free at the primary
site.58 However, on the basis of updated results, some
concern was raised regarding the high mortality rate
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from unknown causes noted during follow-up, which
may have arisen from secondary aspiration, pneumo-
nia, or other unrecognized sequelae of treatment.59
Apart from larynx preservation, overall survival only
shows modest differences at best between the differ-
ent regimens for laryngeal cancer and do not seem to
signiﬁcantly differ from ‘‘traditional’’ surgery followed
by radiotherapy in the treatment of head and neck
cancer in general.60
In 2000, Pignon et al61 published the results of
individual patient data meta-analysis of 63 random-
ized trials on locoregional treatment (surgery or
radiotherapy) with or without chemotherapy, per-
formed between 1965 and 1993. The study involved
10,741 patients with nonmetastatic HNSCC (Meta-
Analysis of Chemotherapy in Head and Neck Cancers).
The investigators found an absolute survival beneﬁt of
4% at 2 and 5 years in favor of the addition of chemo-
therapy. However, in the group of trials on concomitant
chemoradiation, an 8% absolute beneﬁt at 5 years in
the experimental arm was highly signiﬁcant. The
authors concluded at that time that because the analy-
sis showed only a small signiﬁcant survival beneﬁt in
favor of chemotherapy and, in particular, because of the
heterogeneity of the results, which required cautious
interpretation, ‘‘the routine use of chemotherapy is de-
batable’’ and that ‘‘for larynx preservation, the non-sig-
niﬁcant negative effect of chemotherapy in the organ
preservation strategy indicates that this procedure
must remain investigational.’’
Since that time more studies have been con-
ducted, and the results of the meta-analysis of the
updated database of the Meta-Analysis of Chemother-
apy in Head and Neck Cancers group with 87 trials
conducted between 1965 and 2000, with a total of
16,486 patients, was published recently.62 An absolute
survival beneﬁt for chemotherapy of 4.5% at 5 years
conﬁrmed previous results, as did the most pro-
nounced beneﬁt observed in concomitant trials (6.5%
at 5 years). No survival advantage was shown for
induction chemotherapy, although this should be
interpreted with caution as taxane-based induction
chemotherapy trials, which already proved to be
superior to the reference PF combination, were not
included in meta-analysis. This time the authors con-
cluded that ‘‘the beneﬁt of concomitant chemotherapy
was conﬁrmed,’’ and results ‘‘should be useful to
determine standard treatment in this disease.’’ It
should be noted that in the initial as in the updated
results of the meta-analysis, the subset analysis did
not reveal any difference between the different tumor
sites. The beneﬁcial effect of the addition of concomi-
tant chemoradiation reference to radiotherapy alone
was similar among patients with hypopharyngeal
cancer to that observed among patients with other
primary tumor sites.
Increasingly intensive treatment regimens have
been investigated, not only of concomitant chemora-
diotherapy protocols but also sequential approaches
consisting of both induction chemotherapy followed
by radiotherapy alone or concomitant chemoradio-
therapy. The addition of taxanes to the platinum-
based induction chemotherapy seems to further
improve outcomes, especially for laryngeal preserva-
tion. In patients with advanced laryngeal and hypo-
pharyngeal carcinomas, induction chemotherapy
consisting of docetaxel, cisplatin, and 5-ﬂuorouracil
appeared to be superior to a regimen consisting of PF
in terms of overall response rate (complete and partial
responses, 80% vs 59%, p ¼ .002). Larynx preservation
could be achieved for a higher proportion of patients
in the docetaxel-cisplatin-ﬂuorouracil group compared
with the cisplatin-ﬂuorouracil group (at 3 years: 70%
vs 57.5%, p ¼ .03), but again without associated over-
all survival beneﬁt (60% at 3 years in both arms).63
Posner et al64 reported on a similar phase III trial
of sequential therapy comparing docetaxel-cisplatin-ﬂu-
orouracil against cisplatin-ﬂuorouracil induction chemo-
therapy, followed by chemoradiotherapy with weekly
carboplatin. In addition to patients with unresectable
oral cavity, oropharyngeal, hypopharyngeal, or laryngeal
cancer, patients considered to be candidates for organ
preservation were also included (33% and 35% of
patients in each arm of the trial). Laryngectomy-free sur-
vival was signiﬁcantly greater with docetaxel-cisplatin-
ﬂuorouracil: at 3 years 52% vs 32%. Fewer patients
treated with docetaxel-cisplatin-ﬂuorouracil underwent
surgery (22% vs 42%). In this study there was also a sig-
niﬁcant beneﬁt regarding overall survival in favor of
docetaxel-cisplatin-ﬂuorouracil induction chemotherapy.
Another important aspect of nonsurgical
approaches is their potential ability to counteract the
development of distant metastases. Different patterns
of recurrence with fewer initial distant metastases in
the induction chemotherapy group compared to the
surgery group were observed in The Department of
Veterans Affairs’ study,54 which was conﬁrmed by
other authors.65 This may be another argument in
favor of inclusion of systemic agents in organ preser-
vation treatment protocols. Whereas the concomitant
use of irradiation and systemic therapeutics has been
proven to successfully improve locoregional disease
control and to a lesser extent also distant metastases-
free survival,62 the sequential chemoradiation strat-
egies incorporating induction chemotherapy protocols
are aimed at diminishing the incidence of distant fail-
ures. According to the results of a recent meta-analy-
sis this seems to be the case.62
For those patients with M1 disease, prognosis is dis-
mal. Although these patients in particular are directed
to take part in experimental clinical protocols exploring
new systemic drugs and their combinations, the median
survival times are usually less than a year. The results
of studies testing a new treatment paradigm combining
immunotherapeutic and conventional chemotherapeutics
look promising, although tumor sites other than the
hypopharynx were included.66
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It may be concluded from the data of these studies
that intensifying treatment may increase the rate of
larynx preservation but survival beneﬁt has been
reported less consistently.59,67,68 In addition, interpre-
tation of the (sometimes conﬂicting) results of chemo-
radiotherapy trials may be hampered by several
factors. Studies often consist of populations with a dif-
ferent mix of both laryngeal and hypopharyngeal cancer
and end-points are differently deﬁned or chosen.69
TOXICITY OF CHEMORADIATION PROTOCOLS
AND QUALITY OF LIFE
Besides other toxic effects, both acute and late (xero-
stomia, skin toxicity, cervical ﬁbrosis and lymphe-
dema, ototoxicity),70,71 signiﬁcant swallowing
dysfunction is a common ﬁnding after intensive che-
moradiotherapy. In patients with HNSCC, the rate of
symptomatic strictures is estimated to be around
20%, with a hypopharyngeal primary site as a signiﬁ-
cant predictive factor.72 Fixation of the vocal cord, in
particular, seems to be a predictor of poor functional
outcome,73 and even total pharyngeal obstruction
may occur.74 Impaired swallowing function promotes
aspiration, which may lead to pneumonia. Aspiration
pneumonia may be an underdocumented and under-
reported complication of chemoradiotherapy for
HNSCC. Future studies should examine whether rou-
tine posttherapy videoﬂuoroscopy and swallowing
exercise training of patients can reduce this risk.75,76
Functional aspects of the results of the Depart-
ment of Veterans Affairs Laryngeal Cancer Study
Group trial related to communication, swallowing and
eating were reported by Hillman et al.77 From the
viewpoint of speech communication, patients treated
with induction chemotherapy did better than those
with removal of the larynx. For other non–speech-
related measures, there were only a few signiﬁcant
differences between the 2 groups. Only 6% of patients
undergoing total laryngectomy had development of
usable esophageal speech, although the proportion of
those who remained nonvocal was also small (8%).
When assessing long-term quality of life in surviving
patients from the Veterans’ study, more favorable
results were found in non-surgically treated patients.
Better scores in various quality of life instruments
appeared to be related to more freedom from pain,
better emotional well-being, and lover levels of
depression than to preservation of speech function.78
Furthermore, Fung et al79 reported on voice and
swallowing outcomes of an organ preservation phase
II trial for 97 patients with advanced laryngeal can-
cer. They were treated with a single course of PF
induction chemotherapy followed by concurrent che-
moradiation when the response was 50%, or with
salvage laryngectomy when response was assessed to
be less than 50%. Patients with an intact larynx dem-
onstrated better voice-related quality of life than did
patients treated with laryngectomy. Early salvage
(immediately after unsuccessful induction chemother-
apy) was associated with fewer surgical complications
but no difference in voice-related outcome when com-
pared with late laryngectomy (after chemoradiation
failure). Although overall swallowing function was good
in all patients, those with an intact larynx were more
likely to obtain nutrition with oral intake alone with-
out supplements.
Although the above mentioned developments and
innovations have led to more intensive treatment
approaches aimed at the best possible oncologic
results, including laryngeal preservation rate, the
morbidity connected to such treatment has increased
accordingly. Probably the most important factors con-
tributing to morbidity in these patients is dysphagia
and aspiration as a consequence of radiotherapy to
the larynx and pharynx. In this respect, relevant
structures are the pharyngeal constrictors and supra-
glottic larynx.80 More accurate delineation of target
volumes may spare those critical structures. Inten-
sity-modulated radiotherapy (IMRT) offers the possi-
bility of reducing the volumes of these critical
structures receiving high doses,81 although in hypo-
pharyngeal primaries in particular, growing next to
or directly inﬁltrating structures important for intact
swallowing function, such sparing effect of advanced
irradiation techniques is less likely. Indeed, a prospec-
tive observational study showed that patients treated
with IMRT had fewer swallowing problems after com-
pletion of radiotherapy or chemoradiation than
patients treated with conventional three-dimensional
conventional radiotherapy.82 Most centers are also
trying to spare high-dose radiation to one or more of
the major salivary glands with these techniques,
which has a beneﬁcial effect on deglutition.83
Other recent developments are focused on reduc-
ing overlapping toxicity of concomitantly adminis-
tered systemic agents and irradiation, speciﬁcally
acute toxicity, lack of compliance and, consequently,
late effects affecting function and quality of life. One
of these developments is the use of biologic agents as
radiosensitizers such as epidermal growth factor re-
ceptor inhibitors administered concurrently with ei-
ther deﬁnitive radiotherapy or chemoradiotherapy
regimens.84 In a phase III randomized trial of radio-
therapy and radiotherapy plus weekly doses of cetuxi-
mab, in patients with locoregionally advanced
HNSCC, the 5-year overall survival rate was signiﬁ-
cantly improved with the addition of cetuximab,
increasing from 36% to 46%, respectively.85 In sub-
group analysis, patients with oropharyngeal cancer
seemed to beneﬁt more than those with hypopharyng-
eal cancer, but the study was not powered for this
additional analysis. There are no studies on the effec-
tiveness of this treatment regimen in hypopharyngeal
cancer in particular. So although potentially promising,
possibly in combination with existing chemoradiother-
apy regimens, the role of targeted systemic therapies in
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the treatment of hypopharyngeal cancer remains to be
established. Moreover, although intended to be less toxic,
there may still be considerable side effects, particularly
when used in combination with chemoradiotherapy.
Finally, in a study on quality of life of patients
with HNSCC, no signiﬁcant difference was found in
overall health-related quality of life between patients
treated with surgery followed by radiotherapy and
patients treated with chemoradiation. The authors
stated that because nonsurgical means of treating head
and neck cancer have become more aggressive and sur-
gical techniques have become more focused on function
preservation and rehabilitation, the outcome from
these 2 approaches is similar in terms of overall
health-related quality of life.86 In a long-term longitu-
dinal study of quality of life, the presence of a feeding
gastrostomy was found to be the variable most closely
associated with poor quality of life.87 This contrasts
many surgeons’ perception that the need for long-term
tracheostomy or tracheostoma is the most serious func-
tional sequel of treatment. However, the symbolic im-
portance for the patients of keeping an intact larynx
should not be underestimated. The French larynx pres-
ervation trial on induction chemotherapy conducted in
the 1990s had to be closed prematurely because of
strong patients’ preference for the larynx preservation
arm and insufﬁcient accrual into the total laryngec-
tomy arm.88
SALVAGE SURGERY
Although the focus of this article is on initial treat-
ment, salvage surgery could be considered part of
planned treatment by nonsurgical approaches. High
rates of patient survival in larynx preservation trials
are achieved because of effective salvage surgery for
locoregional recurrences. The timing and means of sur-
veillance and intervention are still a matter of
debate,89,90 but are undoubtably of importance. In the
initial phase of the chemoradiation era planned neck
dissections were the rule. Later it was realized that
not all patients needed neck dissection. Conscientious
surveillance and timely identiﬁcation of those patients
with resistant or recurrent disease for neck dissection
made planned neck dissection obsolete.91 Adequate
and timely salvage surgery is important to obtain sat-
isfactory locoregional control rates in cases of non-
surgical treatment strategies. 5-year local and
regional control rates for salvage pharyngectomy
have been reported in 71% and 70% of the cases,
respectively.92 However, less favorable results have
also been reported. In a series reported by Relic et
al,93 only 2 of 20 patients undergoing surgery for
histologically proven recurrence of laryngeal or
hypopharyngeal cancer after chemoradiotherapy
were tumor-free and alive after a mean observation
time of 44 months.
Moreover, the rate of complications of surgery af-
ter chemoradiation has increased. For example, a
high (up to 75%) rate of ﬁstulas has been reported,
depending on the interval between completion of
radiotherapy and salvage surgery, and the dose of
radiotherapy. Salvage surgery is associated with long-
term stricture rates of 15%.92,94–96
CONCLUSIONS
Efforts to preserve speech and swallowing function in
the treatment of hypopharyngeal (and laryngeal) can-
cer have resulted in a declining use of TLP. Surgical,
as well as nonsurgical, options are available in an
attempt to achieve these goals without losing the
efﬁcacy of treatment or ultimate tumor control and
survival. However, when comparing data on survival,
it should be kept in mind that the populations
that have been treated with certain modalities are
often selected and therefore comparison of results
is difﬁcult and should be done with caution
(Table 1).4,7,12,21,22,30,31,34–36,41–45,49,51–53
With surgical approaches, PLP, as an open proce-
dure or performed endoscopically as a less traumatic
minimally invasive procedure, have offered the oppor-
tunity of preserving function of the larynx in selected
cases of hypopharyngeal cancer. However, only
selected cases will be suitable for this approach.
Many patients have beneﬁted from the develop-
ments in nonsurgical treatment. A signiﬁcant number
of these patients retain their larynx, which otherwise
would have been removed. The treatment is applica-
ble to a wide spectrum of hypopharyngeal cancers,
including intermediate-stage disease; only extensive
disease with loss of function at presentation could best
be treated with TLP as the primary option. However,
although increasingly toxic chemoradiation protocols
may further improve larynx preservation rates, this
could be associated with signiﬁcantly more pronounced
toxicity and worse functional results. Developments
aimed at improving results without increasing toxicity
and morbidity are focused on technical improvements
in radiotherapy, advances in supportive care and the
use of new targeted therapy agents other than
chemotherapeutics.
In early-stage disease, both surgery and radio-
therapy are organ and function preserving treatment
options. However, the role of surgery in early-stage
hypopharyngeal cancer is less established than for la-
ryngeal cancer. The choice of treatment may depend
on patient-related factors like age, comorbidity,97
occupation, patient preferences, and tumor-related
factors such as size and localization. In advanced dis-
ease, most patients will be treated either with TLP
followed by (chemo)radiotherapy or up-front chemora-
diation. In selected cases partial surgery may be con-
sidered, but experience is greater with laryngeal
cancer than with hypopharyngeal carcinoma, and
favorable results can only be obtained in carefully
selected patients and treatment by highly experienced
teams.
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When comparing nonsurgical and surgical treat-
ment options, not only are traditional oncologic out-
come measures important. Functional outcome and
quality of life, in particular, are important as well. The
latter studies are relatively scarce. Although chemora-
diation has gained substantial popularity and seems to
be an important treatment option at other sites of the
head and neck, in hypopharyngeal cancer this is less
obvious, both in terms of oncologic, as well as func-
tional outcome. Lack of studies employing nonsurgical
treatments exclusively in hypopharyngeal cancer pre-
cludes deﬁnitive conclusions.
The success of organ preservation protocols in la-
ryngeal cancer has led to an increase in the use of
primary chemoradiation in both laryngeal and extra-
laryngeal primary sites, despite a paucity of random-
ized clinical trial data comparing nonsurgical
treatment to the ‘‘gold standard’’ of surgery followed
by postoperative radiation for unfavorable pathologic
features, and an increasing recognition that the high
surgical salvage rates enjoyed by patients with laryn-
geal cancer do not necessarily translate to extralaryng-
eal sites. Therefore, despite the declining use of (open)
surgery, the role of primary surgery in head and neck
cancer should perhaps be reviewed.98
Although the emphasis has been shifted to non-
surgical treatments, these strategies still involve sur-
gical procedures. Thus the role of the surgeon in
treatment and follow-up remains important,99 not
only as an option for initial treatment, but also for sal-
vage, tumor surveillance and the diagnosis and treat-
ment of complications and functional impairments.
It is recognized that future studies need to be
carefully designed with clearly deﬁned populations
and uniformity in terminology and endpoints.15,69
Moreover, whereas most larynx preservation trials
enroll patients with either laryngeal or hypopharyng-
eal cancer, it should be realized that these tumors are
distinct entities. Results in laryngeal cancer may not
directly translate to those in hypopharyngeal cancer.
Therefore, speciﬁc trials for hypopharyngeal cancer
would be needed.
Table 1. Survival rates of patients treated with different treatment modalities for hypopharyngeal cancer.
Treatment
No. of
patients
Overall survival, 5 year
(4 year) [3 year] {2 year}
Disease-speciﬁc survival, 5 year
(4 year) [3 year]
TLP
Kraus et al4 132 30% 41%
Frank et al21 110 18%* —
48% —
Bova et al22 180 33% 52%
Ogura et al30 57 [36%] —
Partial surgery
Open procedures
Ogura et al30 85 [59%] —
Laccourreye et al31 34 (T2) — 56%
Chevalier et al34 48 (T1/T2) 47% —
T1:78%
T2:38%
Makeieff et al35 87 (T1/T2) 60% —
T1:83%
T2:50%
Plouin-Gaudon et al36 34 50% 65%
Transoral procedures
Steiner et al41 129 71% (stage I/II) 95% (stage I/II)
47% (stage III/IV) 69% (stage III/IV)
Rudert and Ho¨ft42 29 48% 58%
Vilaseca et al43 28 (43%) (59%)
Kutter et al44 58 {78%} —
Martin et al45 172 68% (stage I/II) 96% (stage I/II)
64% (stage III) 86% (stage III)
41% (stage IV) 57% (stage IV)
Radiotherapy
Gupta et al7 501 — [41%]
Godballe et al49 101 16% 28%
Yoshimura et al51 77 (stage I/II) 47% 74%
Nakamura et al52 115 (stage I/II) 66% 77%
Rabbani et al53 123(stage I/II) 35% 61%
Chemoradiotherapy
Lefebvre et al12 100 [57%] [43%]
25%
Abbreviation: TLP, Total laryngopharyngectomy.
*Without postoperative radiotherapy.
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It is plausible that selection is important in the
choice of optimal treatment strategies. For surgical
approaches to organ preservation, T classiﬁcation,
anatomic sublocalization, and extension of the pri-
mary tumor are more relevant selection criteria than
the overall disease stage. In cases of nonsurgical
treatment, volume of the primary tumor may be a
predictive factor.100 How other factors such as a
patient’s immune reactivity and the innate biology of
an individual tumor relates to prognosis and therapy
selection have yet to be explored. Most trials involv-
ing nonsurgical treatment strategies report on overall
stage rather than T and N classiﬁcation but stage
may be a suboptimal criterion for selection of treat-
ment. Small primaries classiﬁed as T1 and T2 but
with extensive nodal metastases will be staged as IV
and must be considered separately from large T4
tumors that are otherwise staged similarly.101 A small
primary tumor might very well be treated by partial
surgery followed by postoperative radiotherapy when
indicated. More extensive primary tumors will not be
suitable for organ preserving surgery and may better
be treated with chemoradiotherapy regimens with the
intention of organ preservation. Very extensive pri-
mary tumors with extensive destruction and func-
tional impairment of the larynx may be best treated
with initial laryngopharyngectomy.
Thus, the clues to better oncologic, as well as
functional, outcomes are probably to be found in
appropriate patient selection. However, the optimal
means for selection may be difﬁcult to determine.
Until more evidence is available to decide reliably
about optimal treatment for the individual patient,
each patient should be discussed by knowledgeable
multidisciplinary teams weighing the many factors and
options that inﬂuence an optimal and individualized
treatment recommendation.
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